Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (26)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Airò, P.
Right arrow Articles by Toniati, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Airò, P.
Right arrow Articles by Toniati, P.
Related Collections
Right arrow Vasculitis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2002; 41: 347-349
© 2002 British Society for Rheumatology

Letters to the Editor

Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs

P. Airò, C. M. Antonioli, M. Vianelli and P. Toniati

Clinical Immunology, Spedali Civili, Brescia, Italy

SIR, The therapeutic approach to giant cell arteritis (GCA) remains based on the long-term use of high doses of corticosteroids. No real alternative exists in cases in which the disease is not controlled or recurs despite appropriate therapy with steroids, or in which unacceptable side-effects arise. Although small studies have suggested that immunosuppressive drugs, such as azathioprine and methotrexate, could be used as steroid-sparing agents [1. . . [Full Text of this Article]

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
V M Martinez-Taboada, V Rodriguez-Valverde, L Carreno, J Lopez-Longo, M Figueroa, J Belzunegui, E M Mola, and G Bonilla
A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects
Ann Rheum Dis, May 1, 2008; 67(5): 625 - 630.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
A L Tan, J Holdsworth, C Pease, P Emery, and D McGonagle
Successful treatment of resistant giant cell arteritis with etanercept
Ann Rheum Dis, April 1, 2003; 62(4): 373 - 374.
[Full Text] [PDF]